
    
      Gastric cancer patients who diagnosed as Borrmann type 4 would be included in this study.They
      would receive 3 cycles of neoadjuvant chemotherapy with SEEOX regimen via combined
      intra-arterial and intravenous administration. The treatment schedule consisted of 3 courses
      (each, 2-week administration and 1-week withdrawal) of intra-arterial administration of
      oxaliplatin (150mg), etoposide (100mg) and epirubicin(30mg) by Seldinger method on day 1 and
      oral S-1(120mg) on days 1-14, followed by radical surgery.The efficacy and toxicity of SEEOX
      regimen would be examined.
    
  